Belsomra now available in the U.S. to treat insomnia

Merck & Co. has confirmed that the orexin receptor antagonist Belsomra (suvorexant) is now available at U.S. pharmacies for the treatment of insomnia in adults who have difficulty falling asleep and/or staying asleep.

The recommended dose of the product is 10 mg, taken no more than once per night and within 30 minutes of going to bed, with at least 7 hours remaining before the planned time of awakening (Merck & Co. News Release).